Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.

"Disclosures Dr Watanabe reports honoraria from Abbott Medical, Abiomed, Bayer, Bristol-Myers, Daiichi Sankyo, Kowa, Phizer, and Otsuka; support for attending meetings from Abbott Medical. Dr Morimoto reports lecturer’s fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray; manuscript fees from Bristol-Myers Squibb and Kowa; participation on advisory board for Sanofi. Dr Natsuaki reports honoraria from Abbott Medical. Dr Suzuki reports honoraria from Abbott Medical. Dr Tanabe reports honoraria from Abbott Medical, AstraZeneca, Boston Scientific, Daiichi Sankyo, Japan Lifeline, and Terumo; participation on advisory board for Abbott. Dr Morino reports honoraria from Abbott Medical. Dr Kadota reports honoraria from Abbott Medical. Dr Furukawa reports honoraria from Bayer, Daiichi Sankyo, and Sanofi. Dr Nakagawa reports research grant from Abbott Medical; honoraria from Abbott Medical, and Daiichi Sankyo; participation on advisory board for Abbott. Dr Kimura reports research grant from Abbott Medical, and Boston Scientific; honoraria from Abbott Medical, Boston Scientific, Daiichi Sankyo, Sanofi, and Terumo; participation on advisory board for Abbott Medical, Boston Scientific, and Sanofi. The other authors report no conflicts."

"Sources of Funding This work (STOPDAPT-2 [Short and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2] and STOPDAPT-2 ACS) was supported by Abbott Vascular Japan. The study sponsor is not involved in the implementation of the study, data collection, event fixation and statistical analysis. However, approval of the study sponsor should be obtained for presentation in scientific meetings and submission of papers."

"Registration:: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT02619760, NCT03462498."